Celyad Oncology/ BE0974260896 /

12/8/2023 5:35:20 PM	Chg. -0.0140	Volume	Bid5:35:21 PM	Ask5:40:00 PM	High	Low
0.3750EUR	-3.60%	44,112 Turnover: 16,826.5760	0.3750Bid Size: 1,799	0.3900Ask Size: 5,500	0.3960	0.3750

GlobeNewswire 3/24/2022 Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights

GlobeNewswire 3/17/2022 Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

GlobeNewswire 3/2/2022 Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

GlobeNewswire 2/28/2022 Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

GlobeNewswire 1/31/2022 Celyad Oncology Announces February 2022 Conference Schedule

GlobeNewswire 1/10/2022 Celyad Oncology Provides Outlook for 2022

GlobeNewswire 12/31/2021 Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

GlobeNewswire 12/22/2021 Celyad Oncology Announces January 2022 Conference Schedule

GlobeNewswire 12/17/2021 Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2...

GlobeNewswire 12/16/2021 Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

GlobeNewswire 12/15/2021 Transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2...

GlobeNewswire 12/13/2021 Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Ex...

GlobeNewswire 12/8/2021 Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group ...

GlobeNewswire 12/3/2021 Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group

GlobeNewswire 11/12/2021 Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE...

GlobeNewswire 11/10/2021 Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights

GlobeNewswire 11/4/2021 Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual ...

GlobeNewswire 11/2/2021 Celyad Oncology Announces November 2021 Conference Schedule

GlobeNewswire 10/29/2021 Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

GlobeNewswire 10/1/2021 Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunothe...

GlobeNewswire 9/1/2021 Celyad Oncology Announces September 2021 Conferences Schedule

GlobeNewswire 8/4/2021 Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

GlobeNewswire 8/4/2021 T-knife Therapeutics Appoints Peggy Sotiropoulou, Ph.D. as Chief Scientific Officer

GlobeNewswire 7/30/2021 Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

GlobeNewswire 7/29/2021 Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call